ClinicalTrials.gg
TerminatedNCT00821717EFFICACY-HFUpdated Jun 3, 2015

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

A Phase 3 interventional study of Ferinject ® (Ferric carboxymaltose) and Normal saline (0.9%) in Chronic Heart Failure, Iron Deficiency and Iron Deficiency Anemia, sponsored by Vifor Pharma. Terminated at 41 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-03.

Primary conditionAnemia, Iron-DeficiencyRegistry: Iron DeficienciesReclassifiedWhy we changed it
Registry
Iron Deficiencies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anemia, Iron-Deficiency
Why
  1. The study's listed conditions name Anemia, Iron-Deficiency, a narrower term within Iron Deficiencies.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Why this study was terminated
Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low recruitment in EFFICACY-HF the decision was made to terminate it.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
41st of 57
35 · median 100
Started
2008
with 2 others
Phase 3
16 of 57
none open now
Registered
4th of 57
by date
Lead sponsor
7 of 57
Vifor Pharma

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 41st largest by enrollment, is one of 3 that started in 2008, is one of 16 in phase 3, and was the 4th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.

03

Conditions studied

  • Chronic Heart Failure
  • Iron Deficiency
  • Iron Deficiency Anemia
  • Anaemia

Browse trials for

Keywords

  • Chronic Heart Failure
  • Iron deficiency
  • Iron deficiency anaemia
  • Anaemia
  • Heart disease
04

In context

Anemia, Iron-Deficiency Reclassified

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

This study's enrollment of 35 is below the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Compared within Anemia, Iron-Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Iron Deficiencies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
  • (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
  • Screening (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
  • Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%

Exclusion criteria

Exclusion Criteria:

  • History of acquired iron overload.
  • Known active infection, bleeding, active .
  • Chronic liver disease and/or screening (ALT) or aspartate transaminase (AST)
  • Anaemia due to reasons other than iron deficiency
  • therapy or renal dialysis (current or planned within the next 6 months).
  • History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
  • Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
  • Acute myocardial infarction or acute coronary syndrome, or stroke within the last 3 months.
  • Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    1:

    Drug: Ferinject ® (Ferric carboxymaltose)

  • Placebo comparator
    2

    Drug: Normal saline (0.9%)

Interventions

  • Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit. After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).

  • DrugNormal saline (0.9%)

    During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.

07

What researchers measure

Primary outcomes

  1. The distance covered in six-minute walk tests performed at 4, 12 and 24 weeks

    Time frame: 24 weeks

  2. NYHA class assessed at weeks 4, 12 and 24 after the start of study treatment

    Time frame: 24 weeks

Secondary outcomes

  1. Cardiac function assessed by 2D Echo/Doppler cardiography

    Time frame: 24 weeks

  2. Self-reported patient global assessment of treatment

    Time frame: 24 weeks

  3. QOL as assessed by the European Quality of Life - 5 Dimensions and Kansas City Cardi

    Time frame: 24 weeks

08

Study locations

41 sites
  • Research Site
    Copenhagen S, Denmark
  • Research Site
    Esbjerg, Denmark
  • Research Site
    Fredericia, Denmark
  • Research Site
    Glostrup, Denmark
  • Research Site
    Hellerup, Denmark
  • Research Site
    Herning, Denmark
  • Research Site
    Hilleroed, Denmark
  • Research Site
    Svendborg, Denmark
  • Research Site
    Boulogne, France
  • Research Site
    Dijon, France
  • Research Site
    Lyon, France
  • Research Site
    Montpellier, France
  • Research Site
    Nantes, France
  • Research Site
    Pontoise, France
  • Research Site
    Rennes, France
  • Research Site
    Saintes, France
  • Research Site
    Strasbourg, France
  • Research Site
    Dueren, Germany
  • Research Site
    Frankfurt, Germany
  • Research Site
    Homburg/Saar, Germany
  • Research Site
    Koeln, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Würzburg, Germany
  • Research Site
    Afula, Israel
  • Research Site
    Ashkelon, Israel
  • Research Site
    Haifa, Israel
  • Research Site
    Holon, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Kfar-Saba, Israel
  • Research Site
    Rehovot, Israel
  • Research Site
    Tel-Aviv, Israel
  • Research Site
    Tel-Hashomer, Israel
  • Research Site
    Zefat, Israel
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Den Bosch, Netherlands
  • Research Site
    Eindhoven, Netherlands
  • Research Site
    Heerenveen, Netherlands
  • Research Site
    Leiden, Netherlands
  • Research Site
    Nieuwegein, Netherlands
  • Research Site
    Tilburg, Netherlands
  • Research Site
    Utrecht, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2009
First posted
Jan 13, 2009
Start
Dec 2008
Primary completionActual
Oct 2009
CompletionActual
Jan 2011
Last update
Jun 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00821717
Lead sponsor
Vifor Pharma
Collaborators
Socar Research SA
Responsible party
Sponsor
First posted
Jan 13, 2009
Start date
Dec 2008
Primary completion
Oct 2009
Completion
Jan 2011
Last update
Jun 3, 2015

Study contacts

Michael Motro, MD, FACC
study chair · Sheba Medical Center, Tel-Hashomer 52621, Israel

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion